Notice of Proposed Sale · 144

Nurix Therapeutics, Inc.

NRIXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Oct 2, 2026Accepted Oct 2, 2026, 4:19 PM EDTFiling CIK 1817199Accession 0001950047-26-010001

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: NURIX THERAPEUTICS INC
Issuer CIK: 0001549595
SEC file number: 001-39398
Phone: 4156605320
Person for whose account securities are to be sold: CHRISTINE RING
Relationships to issuer: Officer
Street: 1600 Sierra Point Parkway
City: Brisbane
State / country code: CA
Postal code: 94005

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	5,786	135,045.24	103,781,683	10/02/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	10/02/2026	Exercise of Stock Options	Issuer	5,786	N	10/02/2026	Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 4 reported rows
Seller	Security	Sale date	Amount sold	Gross proceeds
10b5-1 Sales for CHRISTINE RING	Common	09/02/2026	5,787	149,072.54
10b5-1 Sales for CHRISTINE RING	Common	08/03/2026	5,787	133,367.20
10b5-1 Sales for CHRISTINE RING	Common	08/03/2026	10,802	248,991.54
CHRISTINE RING	Common	07/30/2026	3,847	89,953.63

Seller — prior-sale row 1, entry 1

Name: 10b5-1 Sales for CHRISTINE RING
Street: 1600 Sierra Point Parkway
City: Brisbane
State / country code: CA
Postal code: 94005

Seller — prior-sale row 2, entry 1

Name: 10b5-1 Sales for CHRISTINE RING
Street: 1600 Sierra Point Parkway
City: Brisbane
State / country code: CA
Postal code: 94005

Seller — prior-sale row 3, entry 1

Name: 10b5-1 Sales for CHRISTINE RING
Street: 1600 Sierra Point Parkway
City: Brisbane
State / country code: CA
Postal code: 94005

Seller — prior-sale row 4, entry 1

Name: CHRISTINE RING
Street: 1600 Sierra Point Parkway
City: Brisbane
State / country code: CA
Postal code: 94005

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 10/02/2026
Signed: /s/ Christine Ring
Plan adoption dates: 11/10/2025

Company context

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.

Current securities

NRIXNASDAQ · EQUITY · Current

Free Registration